Oct 27, 2009|
Will the RBI change its stance?
All eyes will be on the RBI today as it releases its monetary policy and also gives an indication of where the interest rates are headed. The decision will be tough for the central bank as while on one hand the economy is limping back to recovery, on the other hand, inflation has started picking up. As far as the latter is concerned, the RBI expects it to rise to 5% by the end of this fiscal and it will be interesting to see when it begins to hike interest rates. The RBI had in the past made it clear that it would continue with its expansionary monetary policy till such time that it becomes clear that the recovery is sustainable.
However, the worrying factor here is that inflation is slowly beginning to creep up. Poor monsoons have been instrumental in driving up food prices as crop production was hampered. As a result, the WPI which was languishing in the negative has now moved into the positive territory. What is more, the CPI, where food prices are given more weightage, refuses to budge from its high levels. Not just that, because of India's attractiveness as an investment destination as compared to the developed economies which are mired in recession, FIIs have once again made a beeline for Indian shores. This has swamped the economy with enough liquidity and driven up the stock markets, thereby making a case for hiking interest rates to rein in inflation.
Further, while poor monsoons raised doubts about whether the Indian economy would be able to grow at 6% plus as envisaged by the Finance Minister and the RBI, the strong growth in industrial production seems to have dispelled those fears and could be perceived as a strong sign that the economy is recovering. That is why the RBI's stance in today's monetary policy will be critical in terms of setting the tone with respect to interest rates. At some point in time, it will have to raise interest rates taking into account inflation and rising liquidity. The million dollar question is when. Over to you, Mr. Subbarao.
Pharma results: The verdict so far
Results for pharma companies have started pouring in and they have been heartening as compared to what was witnessed in the previous two quarters. The performance on the topline front has been mixed and subdued conditions in the global markets, especially in Europe and Russia have hampered sales to a certain extent. For instance, Piramal Healthcare's custom manufacturing business witnessed a decline precisely because innovator companies in the US and Europe are in the process of cleaning up their inventories. Similarly, in Russia, Ranbaxy and Dr.Reddy's have witnessed challenging conditions due to the sharp depreciation of the local currency and receivables as a result of which both these companies are focusing more on recovering payments even if that means foregoing some sales.
On the margin front, however, many of them have witnessed considerable improvement due to various cost rationalization measures and improvement in product mix. Not just that, there have not been any nasty surprises on the forex front, which dominated performance in the last two years due to considerable volatility in the way the rupee moved. So, overall profits have grown at a much faster pace than the topline.
Overall, from a long term perspective, the prospects of the pharma sector look intact as the fundamentals in terms of governments across the world veering towards low cost generics have not changed. However, mirroring the Indian stockmarkets, pharma stocks have also rallied considerably over the past few months. Hence, we advice investors to adopt a stock specific approach while investing in the sector.
More Views on News
Jun 10, 2017
Forty Indian investing gurus, as worthy of imitation as the legendary Peter Lynch, can help you get rich in the stock market.
Aug 16, 2017
All across the country, the old gods become devils. New, gluten-free gods take their places...
Aug 16, 2017
And what it has in common with beating the stock market too.
Aug 16, 2017
Ensure your financial Independence, and pledge to start the journey towards financial freedom today!
Aug 14, 2017
Last week's correction is making a number of Super Investor stocks look a lot more attractive...
More Views on News
Aug 7, 2017
The data tells us quite a different story from the one the government is trying to project.
Aug 4, 2017
The small-cap space is full of small players that are clear proxies to great growth stories and Indian megatrends.
Aug 8, 2017
Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...
Aug 12, 2017
The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.
Aug 7, 2017
Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...
Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement. LEGAL DISCLAIMER:
Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here
. The performance data quoted represents past performance and does not guarantee future results.SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: firstname.lastname@example.org. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407